The present study supports the role of MG to modulate NLRP3, NLRC4, and AIM2 inflammasome activation, both in primary cortical microglia and in a mouse model of anxiety and depression, as a potential therapeutic approach to addressing immune-inflammatory-based disorders. This evidence concerns the gene NLRP3 and major depressive disorder.